EMA/472068/2021

European Medicines Agency decision

P/0371/2021

of 8 September 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for concizumab, (EMEA-002326-PIP04-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0371/2021

of 8 September 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for concizumab, (EMEA-002326-PIP04-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novo Nordisk A/S on 26 November 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 July 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for concizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for concizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for concizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novo Nordisk A/S, Novo Allé 1, 2880 – Bagsværd, Denmark.

EMA/PDCO/245654/2021
Amsterdam, 23 July 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-002326-PIP04-20

Scope of the application

Active substance(s):

Concizumab

Condition(s):

Treatment of congenital haemophilia A

Treatment of congenital haemophilia B

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted for agreement to the European Medicines Agency on 26 November 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 January 2021.

Supplementary information was provided by the applicant on 16 April 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of congenital haemophilia A

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

1.2. Condition:

Treatment of congenital haemophilia B

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of congenital haemophilia A

2.1.1. Indication(s) targeted by the PIP

Prophylaxis of bleeding episodes in patients with congenital haemophilia A (factor VIII deficiency), with and without inhibitors

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	3	**Study 1 (NN7415-4311)** Randomised, open label, active-control study to assess efficacy, safety and pharmacokinetics of concizumab prophylaxis as compared to no prophylaxis (bypassing agent on-demand) in congenital haemophilia A and B patients with inhibitors from 12 years to less than 18 years of age (and adults). **Study 2 (NN7415-4307)** Randomised, open label, active-control study to assess efficacy, safety and pharmacokinetics of concizumab prophylaxis as compared to no prophylaxis (factor products on-demand) and to prophylaxis with factor VIII or factor IX in patients with congenital severe haemophilia A or moderate/severe haemophilia B without inhibitors from 12 years to less than 18 years of age (and adults). **Study 3 (NN7415-4616)** Non-randomised, open-label intra-patient controlled, single-arm study with age staggered enrolment, to evaluate efficacy, safety and pharmacokinetics of concizumab prophylaxis versus previous standard of care on-demand and prophylaxis treatment in congenital haemophilia A and B patients with and without inhibitors from 1 year to less than 12 years of age.
Extrapolation, modelling and simulation studies	2	**Study 4** Population PK Modelling and Simulation study to evaluate a suitable dose of concizumab for children from 1 year to less than 18 years of age. **Study 5** Exploratory analysis investigating the relationship between predicted concizumab exposure and treated bleeds.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition:

Treatment of congenital haemophilia B

2.2.1. Indication(s) targeted by the PIP

Prophylaxis of bleeding episodes in patients with congenital haemophilia B (factor IX deficiency), with and without inhibitors

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Solution for injection

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	3	**Study 1** *Same as for condition Treatment of congenital haemophilia A, see above* **Study 2** *Same as for condition Treatment of congenital haemophilia A, see above* **Study 3** *Same as for condition Treatment of congenital haemophilia A, see above*
Extrapolation, modelling and simulation studies	2	**Study 4** *Same as for condition Treatment of congenital haemophilia A, see above* **Study 5** *Same as for condition Treatment of congenital haemophilia A, see above*
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes